Figure 2From: Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agentEfficacy of VSVΔ51 combined with RT or ZD6126 in the FaDu xenograft model. (A) FaDu xenograft tumours were established im in the left leg of CD-1 nude mice to allow for local RT delivery. Mice were then randomized to six groups: a) UV-inactivated VSVΔ51 (1 × 109 pfu i.v.); (b) local tumour RTx2 (5 Gy), 3 days apart; (c) VSVΔ51 (1 × 109 pfu i.v.); (d) RT (5 Gy each) plus VSVΔ51 (1 × 109 pfu i.v.) simultaneously, then 2nd RT (5 Gy) delivered 3 days later; (e) ZD6126 alone (5 mg i.v. in 200 μl); and (f) ZD6126 (5 mg) just preceding 1 × 109 VSVΔ51 i.v. Data are presented as mean leg plus tumour diameter ± S.E. (B) Mice in panel (A) were monitored for survival for up to 70 days. All p-values were calculated using the Two-Way ANOVA analysis in comparison with the UV-inactivated VSV control group; survival comparisons were conducted using the log-rank test. n.s., not significant, *p≤0.05,** p≤0.005, ***p≤0.0005.Back to article page